Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

@FlorianLemaitr5 @EricBillyFR C'est l'étude de Gilead, le labo qui commercialise le Remdesivir......... Le 2ème lien à la fin de cette étude commerciale est celui-là est la conclusion n'est pas la même https://t.co/goQPtCCUlG

@FlorianLemaitr5 @EricBillyFR Pour le Remdesivir, je suis curieux parce que toutes les études ont montré que c'est cher (très cher) et que ça sert à que dalle. Par ex. https://t.co/jNI0BtB80R ou çà https://t.co/P1lBPWQ85E Pour le covid, pourquoi s'être lim

@mpc_xetts @denise_dewald Really no statistical difference. Plus. Not safe. https://t.co/Ljz4BkKPdz

@bob68095936 @WolnoscTV @GrzegorzBraun_ @KoronyPolskiej @KONFEDERACJA_ Co do remdesiviru, masz coś bez konfliktu interesu, takiego wręcz ordynarnego? Jakieś badania nie projektowane przez producenta? Znalazłem coś co pod tym względem wygląda dużo lepiej,

@Standing4Rights @lagerth13136056 @Er_Nope @sanjay_world The WIKI page you supplied, and the section you quoted linked to THIS study. There was a 2% increase in AEs above placebo! 🤪🤣 "Adverse events were reported in 102 (66%) of 155 remdesivir recipients

@JordanA8156 @425digs @LeilaniDowding 20 fold increase in kidney damage https://t.co/djhvN2PKp7 No use against COVID https://t.co/yhXg0sNpAm

@dr_jon_l https://t.co/6d54NtL8R8 https://t.co/EvQD8QI9LD

RT @bosanskakaf: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial https://t.co/…

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial https://t.co/4PIAV7U2kX «More patients in the remdesivir group than the placebo group discontinued the study drug because of adverse events or se

@trifan_tatiana Wikipedia cites a 2020 study on side effects: https://t.co/B4mnS6iGLh

@JordanA8156 @deepdiver501 @Censored4sure @Tophrrr You just refuse to accept the fact that a higher proportion of people died in the remdesivir group than the control group. How about this study? I can send you more, if you’d like… https://t.co/BI6eZCXNKe

@Tophrrr There was no clinical benefits to using remnesivir so why did that use it knowing it could cause kidney failure. https://t.co/GyOZZuDcJD

@palliardi @SenatorRennick @DALupton @canberratimes This stuff. https://t.co/62WbNJvoAt

RT @LukeMor19529310: 7/ Then we found out that Fauci rushed his announcement, because someone released another study to the Lancet, showing…

RT @LukeMor19529310: 7/ Then we found out that Fauci rushed his announcement, because someone released another study to the Lancet, showing…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

Please share with your lawmakers, or if appropriate, your lawyer!

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

@apredi @MdBreathe Bingo https://t.co/gYYIenHfbY

@MdBreathe Fauci & Remdesivir 🔹https://t.co/gbmwLzoPcl 🔹https://t.co/SNDEJwIiet 🔹https://t.co/cHoU4DS9NM 🔹https://t.co/amLMRXurLT 🔹https://t.co/WWeLxQzAWi 🔹https://t.co/WLF7FeKsXH 🔹https://t.co/ZFBCUJjzLo 🔹https://t.co/6OTZlUIEBj 🔹https://t.co/lRvwtW1

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

#rundeathisnear

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

“Run-Death-Is-Near”

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

Yet another damning example of harm to patients.

RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https://t.co/6PHPVNqUJN

RT @keisuke4713: 復習 🇨🇳重度コロナremdesivir(R) :無作為化、二重盲検https://t.co/JyVXHpkaho 重症者に有意臨床効果や抗🦠効果無し R群でplacebo群より有害事象・重篤有害事象で中止18人12%対4人5% うち7人5%…

https://t.co/8krN1Tis5o is link to the actual study.

RT @keisuke4713: 復習 🇨🇳重度コロナremdesivir(R) :無作為化、二重盲検https://t.co/JyVXHpkaho 重症者に有意臨床効果や抗🦠効果無し R群でplacebo群より有害事象・重篤有害事象で中止18人12%対4人5% うち7人5%…

復習 🇨🇳重度コロナremdesivir(R) :無作為化、二重盲検https://t.co/JyVXHpkaho 重症者に有意臨床効果や抗🦠効果無し R群でplacebo群より有害事象・重篤有害事象で中止18人12%対4人5% うち7人5%はR群の呼吸不全かARDS 一部に複数有害事象 36人が薬物中止 うち22人有害事象で、退院や早期🙏等14人 https://t.co/N8xoULfhWd

RT @3Filary: @rieske_piotr @StabrawaL Proszę mi nie zarzucać manipulacji Panie Profesorze a skupić się na faktach. Remdesivir nie ma wpływu…

@dr_jon_l @SeaTeaShaw So did you check EUA study for remdesivir , what is endpoint that was used for approval? What is mortality ratio in the same study? https://t.co/gYYIenHfbY Comment please

@ZoranPrimorac1 @nbakic Ovo je primjeceno cak u EUA studiji koja je koristena za odobrenje, relativna smtrnost je bila veca za 8% https://t.co/gYYIenHN1w

@HectorRossete https://t.co/J9MoWQcZyF "remdesivir no esta asociado con beneficios clinicos estadisticamente significativos" se derrumbo la narrativa covid y ahora tienes que trabajar horas extras, se te cayo la productividad, tus patrocinadores no esta

@ThatWitchUKnow @ReOpenChris No, it is called "Science." https://t.co/6yFdA00q0U

@ThatWitchUKnow @ReOpenChris Remdesivir was stopped early because of adverse events in 18 (12%) https://t.co/6yFdA00q0U

here's a thread on original Remdesivir study that I did in April 2020. https://t.co/pyfZNLijh8 I think that I can fairly claim to have been skeptical of Fauci almost immediately. Long before most current Fauci skeptics.

@Project_Veritas This is NOT a scientific paper. Any such paper would have referred to prior articles such as those two - which indicated lack of both safety & effectiveness. This was before Emergency Use Authorization. But who cared at the time? https

RT @sanchak74: By that time, in May 16th China had said it was garbage ... "In this study of adult patients admitted to hospital for sever…

RT @sanchak74: It is important to see the exact date of Fauci's statement and the day China said the trial failed 29th April, 2020 Imagin…

RT @sanchak74: It is important to see the exact date of Fauci's statement and the day China said the trial failed 29th April, 2020 Imagin…

It is important to see the exact date of Fauci's statement and the day China said the trial failed 29th April, 2020 Imagine the number of lives you would have saved if you had listened to the right source https://t.co/WVpfKTYoXj https://t.co/2gCDUxhm3W

For example, it hadnt registered that China had 2 failed trials ... I just knew about one "remdesivir was not associated with statistically significant clinical benefits." https://t.co/kuP1WCeRJA

Look at the date!

@ImCrescentFresh @AlwaysonRed @DrNeilStone https://t.co/g8g8bnMTbo

@Foumalin1 @VPrasadMDMPH What he did not say is increased mortality by 8% but who cares about that...right? https://t.co/gYYIenHfbY

@c_essene @VPrasadMDMPH Yup even same study they used for approval had 8% rel. mortality increase! https://t.co/gYYIenHfbY

@eppoeh Heb je daar een artikel van? Ik vond wel deze, waaruit ook al bleek dat Remdesivir nogal wat bijwerkingen had en verder weinig betekende voor covidbehandeling. Maar zo'n hoog sterftepercentage had ik nog niet gelezen. https://t.co/f3Np9WHI5c

7-19-2022: Bryan, Texas: For remdesivir, trust only the studies that were done outside of Gilead's bribe money: https://t.co/3OF64vX5rK https://t.co/On6Ro0CvLT https://t.co/IUyTSfzOgw https://t.co/HuGuxuhpnn https://t.co/Nier1CHjoC https://t.co/VBwC3LMyfU

@babouviste @VIsfGSyHb3DyGmM @ARenee1971 @PeterSweden7 Really that’s odd because here is the Lancet publishing a paper on Remdesivir efficacy in treating covid which finds that patients don’t benefit from it. https://t.co/P43Gl9xKBk

By that time, in May 16th China had said it was garbage ... "In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits" But we believe China when it suits us

@BigJohnnyCigar @TheoFleury14 No, Remdesivir is not a successful treatment. Multiple studies showed no difference in patients, and it comes with deadly side effects due to its toxicity. Also, it failed Ebola trial - it killed more people than it helped. A

RT @7thclouds: @Trikerider704 英米いずれでも　#レムデシベル　の副作用に肺機能障害等深刻な副作用の報告はないが英国ランチェットは「#新型コロナウイルス　への効果の有意性疑問 https://t.co/snJXIXA83p」「米国ＦＤＡはレムデシビル…

RT @7thclouds: 重症予防・死亡予防にオミクロンにも有効 ファイザー製薬飲み薬 #パキロビット 点滴薬 #ソトロビマブ 早急に処方を 国際的に効果疑問視レムデシベルとモラヌピレビルを日本の医師がコロナ治療効果で有意性認められないにもかかわらず3割がコロナに無効なレム…

@RICAIFrance @LacombeKarine1 @charles_cazanav https://t.co/Oxsm9T6laL

@AJLoebel @Craftmastah @elonmusk @MartinKulldorff @DrJBhattacharya Remdesivir worked great for most people without ANY kidney damage https://t.co/MHzBrEFqbo

Finally not censored!

@shakemaster_B @jack @Twitter https://t.co/CIJY9FlaTb

@Bell68613972 @RDVSVNZLA https://t.co/mphUC909WS https://t.co/i43CIKDIjl

RT @7thclouds: 重症予防・死亡予防にオミクロンにも有効 ファイザー製薬飲み薬 #パキロビット 点滴薬 #ソトロビマブ 早急に処方を 国際的に効果疑問視レムデシベルとモラヌピレビルを日本の医師がコロナ治療効果で有意性認められないにもかかわらず3割がコロナに無効なレム…

@razumann4 @veen_els https://t.co/8qkmFq6WTr https://t.co/bbQYnoKFuq https://t.co/YTEYliOuN6

https://t.co/WEaAMiFR1D

@rieske_piotr @StabrawaL Proszę mi nie zarzucać manipulacji Panie Profesorze a skupić się na faktach. Remdesivir nie ma wpływu na pacjentów hospit. z covid. Nie piszemy o jego potencjale w 1. dobie infekcji, bo jak obaj wiemy, wtedy pacjent jeszcze nawet n

@m17au @Bupolo_ @_Prometeusz_ Problem is that SAE are show stopper (but ignored) so overall mortality is NEGATIVE https://t.co/gYYIenHN1w